Background-The clinical course of patients with hypertrophic cardiomyopathy and advanced heart failure (HF) subtended by progressive left ventricular dysfunction has received limited attention. Our aim was to assess the outcome of HF and impact of treatment options including the implantable cardioverter-defibrillator and heart transplantation (HT) in patients with hypertrophic cardiomyopathy evaluated at 2 Italian referral centers >3 decades. Methods and Results-All-cause mortality and a combined end point including death, HT, or appropriate implantable cardioverter-defibrillator shock were assessed in 71 consecutive patients with HF not related to outflow obstruction (7% of the entire hypertrophic cardiomyopathy cohort) followed up for 6.1±6.9 years after development of New York Heart Association class III to IV symptoms. At enrollment, left ventricular ejection fraction was <50% in 55 patients and >50% in 16; all had restrictive left ventricular filling. During follow-up, 35 patients died (49%%; 5-year rate, 49%) and 53 met the combined end point (75%; 5-year rate, 62%). Most events occurred in the 3 years after HF onset (17% per year compared with only 3% per year subsequently). Appropriate implantable cardioverter-defibrillator shocks occurred in 11 of 34 implanted patients. Of 37 patients evaluated for HT, 14 were transplanted, 10 listed, and 13 excluded; 2 early post-HT deaths occurred in patients with elevated pulmonary vascular resistance. Eleven of the 14 HT patients were alive at 10±8 years. Conclusions-In hypertrophic cardiomyopathy, advanced HF not associated with outflow obstruction portends a severely unfavorable prognosis, particularly in the first 3 years after onset of symptoms, despite frequently preserved systolic function in about one quarter of the patients. Outcome of HT is favorable but requires early consideration, as the window of opportunity may be short. (Circ Heart Fail.
I n patients with hypertrophic cardiomyopathy (HCM), heart failure (HF) symptoms have 2 distinct pathophysiologies. At one end of the spectrum, HF is the result of severe dynamic outflow obstruction, subtended by a hyperdynamic left ventricle (LV) with little or no fibrotic change. 1, 2 This form of HF is generally reversible after septal reduction therapies, resulting in abolition of symptoms and normalization of survival. 1 At the other end, HF is caused by progressive LV dysfunction, subtended by extensive replacement fibrosis and chamber remodeling. [3] [4] [5] [6] [7] [8] [9] The latter scenario, although infrequent, is irreversible and tends to respond poorly to conventional pharmacological treatment, evolving into a serious therapeutic challenge. 3, 4, [9] [10] [11] Previous studies have focused on the so-called end-stage or burned-out phase of HCM, arbitrarily defined by a LV ejection fraction (EF) <50%, which represents a severe condition raising consideration for aggressive management irrespective of symptomatic status. 4, 10 However, such definition fails to capture the range of clinical manifestations associated with disease progression in HCM. Indeed, patients with LVEF<50% may have only limited symptoms and signs of HF, with slow clinical progression into advanced age. 3 These patients may never become candidates for aggressive therapeutic options such as heart transplantation (HT). [12] [13] [14] [15] [16] Conversely, young HCM patients with restrictive evolution may develop severe HF requiring aggressive management despite LVEF values well above 50%. 13 Therefore, the overall burden of advanced HF related to HCM progression, defined by clinical rather than instrumental indices of cardiac dysfunction, remains unresolved. 17 In the present study, we took advantage of the extended experience at 2 Italian referral centers for HCM, including a regional cardiac transplant unit, to assess the prevalence and the clinical course of patients with advanced HF and progressive LV dysfunction. In this setting, the impact of comorbidity and role of available treatment options were specifically evaluated >3 decades.
Methods

Study Population
We retrospectively assessed 1014 patients with HCM (age at initial evaluation, 44±15 years; 55% men) consecutively referred between 1980 and 2012 to the 2 participating referral centers: Careggi University Hospital, Florence (n=889), and Brotzu Hospital, Cagliari (n=125); all patients had at least 1 follow-up evaluation. Diagnosis of HCM was based on 2-dimensional (2D) echocardiographic evidence of a hypertrophied (maximal wall thickness, 15 mm), nondilated LV, in the absence of another cardiac or systemic disease that could produce the magnitude of hypertrophy evident. 1, 2, 10, 11 During follow-up, severe HF symptoms (New York Heart Association III-IV) were developed in 233 patients (23%) on at least 1 occasion; in most (n=162) these were because of LV outflow tract obstruction associated with normal or hyperdynamic LV systolic function. 18 In the remaining 71 (7%), representing the focus of the present study, HF symptoms developed in the absence of obstruction and were associated with evidence of adverse LV remodeling and functional deterioration. 3 The study protocol was approved by the respective internal review boards.
Follow-Up
The time interval from onset of NYHA class III to IV (initial evaluation for this study) to most recent visit, HT or death (final evaluation), was 6.1±6.9 years. Patients were followed up with 12-lead ECG, echocardiography, and 24-hour ECG Holter monitoring at regular intervals of 6 to 12 months, or more often if dictated by clinical status. Pharmacological therapy was prescribed according to current HCM guidelines. 1, 2 Patients aged <65 years were evaluated for HT according to the criteria adopted by the International Society for Heart and Lung Transplantation, 19 including the presence of severe HF symptoms and disease progression refractory to standard medical treatment, reflected by cardiopulmonary test results (peak VO 2 <12 or <14 mL/kg per minute in patients intolerant of β-blockers). All patients evaluated for listing underwent an exhaustive clinical screening to detect possible contraindications to HT.
An implantable cardioverter-defibrillator (ICD) was offered to survivors of cardiac arrest or sustained ventricular arrhythmias or for primary prevention in high-risk patients evaluated on the basis of established risk markers for sudden cardiac death, including LVEF<50% consistent with end-stage disease. 4 Cardiac resynchronization therapy was considered in the presence of LV systolic dysfunction associated with complete left bundle branch block.
Study End Points
Clinical end points used in this study were (1) all-cause mortality; (2) a combined end point including all-cause mortality, HT, or appropriate ICD shocks, whichever occurred first. Only shocks occurring in response to ventricular fibrillation or fast ventricular tachycardia (>180 beats per minute) were considered in this analysis, to minimize the inclusion of non-life-threatening events. HFrelated death was defined as related to cardiac decompensation and progressive disease course, including stroke-related deaths. Sudden cardiac death was defined as unexpected sudden collapse occurring <1 hour from the onset of symptoms in patients who had previously experienced a relatively stable or uneventful clinical course, or occurring during sleep. 17
Echocardiography
Transthoracic echocardiography was performed using commercially available equipment. Standard evaluation included M-mode, 2D and Doppler study, according to the recommendations of the American Society of Echocardiography. 20, 21 LVEF was measured by the biplane Simpson method. A restrictive LV filling pattern was defined as ratio of early:late velocity of mitral inflow ≥2 associated with deceleration time ≤150 ms (or a deceleration time <120 ms in patients with atrial fibrillation). 20 As a part of their evaluation at baseline or after the new onset or variation of symptoms, patients were systematically referred for exercise echocardiography, to identify or exclude the presence of obstruction and assess functional capacity. In the present cohort, none of the patients developed significant outflow gradient during the test. 22
Cardiovascular Magnetic Resonance
Cardiovascular magnetic resonance examinations were performed using commercially available scanners (Philips ACS-NT 1.5T; Gyroscan-Intera, Best, Netherlands, and General Electrics Signa Excite HD 1.5) and work-stations (View Forum; Philips Medical System, Best, Netherlands; Advantage Windows 4.0; General Electric Medical System) as previously described. 23 The presence of late gadolinium enhancement (LGE) was assessed by visual inspection 15 minutes after intravenous administration of 0.2 mmol/kg gadolinium-DTPA (Magnevist; Schering, Berlin, Germany) with breath-held segmented inversion-recovery sequence (inversion time, 240-300 ms), which was acquired in the same views as the cine images. A threshold of 6 SDs exceeding the mean for nonenhanced myocardium was used to define areas of LGE, quantified according to the methodology proposed by Harrigan et al. 24 
Genetic Testing
Genetic counseling and mutational analysis were routinely offered to all patients, as a part of the standard policy followed at our centers, since 2001 in Florence and since 2005 in Cagliari. After informed consent was obtained, patients were screened for mutations in the protein-coding exons and splice sites of 8 myofilament genes, including myosin binding protein C 3, β-myosin heavy chain 7, the regulatory and essential light chains (MYL2 and MYL3), troponin-T type 2, troponin-I type 3, tropomyosin α1, and α-actin, as previously described. 25 
Statistical Methods
Data were expressed as mean±SD. Unpaired and paired Student t test was used, as appropriate, for comparison of normally distributed data. The χ 2 test or Fisher test were used, as appropriate to compare noncontinuous variables expressed as proportions. Survival curves were constructed according to the Kaplan-Meier method, and comparisons were performed using the log-rank test. P values are 2 sided and considered significant when <0.05. Calculations were performed with SPSS 18.0 software (Chicago, IL).
Results
Clinical Features at Onset of HF Symptoms
The 71 patients with HCM with NYHA class III to IV HF symptoms unrelated to LV outflow obstruction represented 7% of the whole HCM cohort followed up at the 2 participating institutions >3 decades. Age at first HCM diagnosis was 44±15 years; 55% were men. First, development of NYHA class III to IV class symptoms (initial evaluation for the study) was at age 53±15 years (range, . Age at final evaluation (or HT or death) was 59±5 years. Severe HF was present at first diagnosis of HCM in only 20 of the 71 patients (28%); the remaining 51 (72%), initially in NYHA class I or II, showed symptom progression after an average follow-up of 8.1 years. Clinical features at initial evaluation are shown in Table 1 . November 2015
Genetic Status
In 37 (74%) of the 50 patients who underwent genetic testing, we identified 30 pathogenic or likely pathogenic mutations, 5 of which were novel. Of these, 19 were missense, 4 splice-site, 5 frameshift, and 2 were nonsense mutations. Specifically, 29 of the 37 patients (78%) had mutations in myosin binding protein C 3, 10 (27%) in myosin heavy chain 7, and 1 each (3%) in troponin-T type 2, troponin-I type 3, MYL2, tropomyosin α1, and actin α1. Ten patients (27% of the genotyped subset) had complex genotypes including 7 with double and 3 with triple mutations.
Evidence of LV Dysfunction
Echocardiographic features at initial evaluation are shown in Table 1 . Marked left atrial dilatation was evident at this stage (51±12 mm); however, average LVEF was relatively preserved (54±13%). Disease progression was subtended by 3 distinct echocardiographic profiles: patients presenting with systolic dysfunction at initial evaluation (EF<50%; n=21), patients with initially preserved EF (range, 52%-69%) who developed systolic dysfunction during follow-up (n=34), and patients with persistently preserved EF (EF>50%; n=16). Average decline in LVEF was 24±11% of the initial value (including 39 patients who lost ≥10%); average LVEF at final evaluation was 39±13% (Figure 1 ). Only a minority of patients showed progressive LV dilatation with end-diastolic diameter increase ≥10 mm (n=16 or 22%; range, ≤31 mm), or wall thinning >5 mm (n=19 or 27%; range, ≤16 mm; Figure 2 ). A restrictive LV filling pattern was present in all patients at final evaluation; 8 patients had severe mitral regurgitation, because of endocarditis in 1 and annulus dilatation secondary to LV remodeling in 7.
Only 21 of the 71 patients (30%) performed cardiovascular magnetic resonance, because of the presence of ICD or other contraindications in the remaining patients. In the subset who performed cardiac cardiovascular magnetic resonance, extensive LGE (>20% of the LV) was present in 11 (52%), lesser degrees of LGE were present in 6 patients (28%), whereas LGE was absent in only 4 (20%).
Management
Pharmacological treatment of the study cohort is detailed in Table 1 . Overall, 34 patients (48%) underwent ICD implantation, including 13 with cardiac resynchronization therapy, at an age of 48±15 (range, 9-72) years. Of these, 31 patients were implanted for primary and 3 for secondary prevention. Other surgical interventions during follow-up are listed in Table 1 .
Clinical Outcome
Follow-up from onset of advanced HF symptoms to most recent evaluation or death was 6.1±6.9 years. During this time, 35 of the 71 patients died (49%) because of refractory HF (n= 22), sudden cardiac death (n=1), cardioembolic stroke (n=2), or other causes including cerebral hemorrhage and complications of HT (n=7; Figure 3 ). Furthermore, 53 patients (75%) met the combined end point including death, HT, or appropriate ICD shock. Eleven of the 34 patients with ICD experienced appropriate shocks, 36±26 months after implantation. Fourteen patients were transplanted (20%; including one with previous ICD shock). Eight of the patients who died had previously been transplanted (n=3) or had received an appropriate ICD shock (n=5; Table 2 ). At 1, 3, and 5 years, all-cause mortality rates were 12%, 43%, and 49%, respectively, whereas the combined end point rates were 20%, 51%, and 62%, respectively (Figure 4 ). Of note, most events occurred in first 3 years after onset of HF symptoms, during which the annual rate for the combined end point was 17% when compared with only 3.1% per year during subsequent follow-up.
There was no difference in all-cause mortality or combined end point rates between patients with LVEF <50% and ≥50% (P>0.2 for both comparisons). The 3 different profiles of disease progression showed similar mortality rates at end of follow-up: 12% per year in patients presenting with systolic 
Feasibility and Outcome of HT
Thirty-seven patients aged ≤65 years at initial evaluation, with refractory HF despite maximum tolerated therapy, were evaluated for HT (Table in the Data Supplement). In this group, initial LVEF was markedly reduced (33±11%) although 5 patients (14%) had a preserved systolic function (range, 53%-65%). All had restrictive LV filling pattern.
Fourteen of the 37 patients were transplanted 8±7 months from listing, at 43±12 years of age. Of these, 11 (79%) were still alive 10±8 years after transplant (≤19 years). Two post-HT deaths occurred early after surgery, because of acute right ventricular decompensation and multiorgan failure, both in patients with elevated and poorly reversible pulmonary vascular resistance pre-HT. The third patient, who presented early acute rejection, died suddenly 1 year after HT (Figure 3 ). Of the remaining 23 patients considered for HT, 4 died on waiting list, 6 were listed, and 13 were excluded from HT because of severe comorbidities (n=5), psychological reasons/patient refusal (n=4), and elevated pulmonary vascular resistances (n=4; Table in the Data Supplement).
Discussion
Prevalence and Substrates of Advanced HF in HCM
Despite a highly complex pathophysiology, HCM is compatible with normal longevity, allowing stable hemodynamic and clinical equilibrium over decades. [1] [2] [3] 10, 11 In a relevant subset of patients, however, progressive decline in LV function leads to clinical deterioration and HF, generally subtended by fibrous substitution of the myocardium. 3, 4, 23 Such evolution may occur in any age group, including children, and is often insidious as symptoms become relevant only when LV dysfunction is advanced. 3 In the absence of specific causal therapies, management of these patients is challenging and may require aggressive options including HT. [13] [14] [15] [16] In the present study, based on the combined cohorts followed up at 2 referral centers >3 decades, 7% of evaluated patients with HCM either presented with or developed advanced HF symptoms during follow-up, with a mean age of onset of 53±15 years (ranging from 13 to 90 years). This figure is roughly in agreement with the existing literature on the prevalence so-called end-stage phase of HCM. [4] [5] [6] [7] [8] Within the continuum of HCM disease progression, 3 different profiles could be identified, ie, patients presenting with systolic dysfunction, with initially preserved EF evolving to systolic dysfunction, and with persistently preserved EF. 3, 13 Despite the distinct phenotype in these 3 subsets, outcome was comparably severe in all. These findings emphasize the need for active surveillance in symptomatic nonobstructive HCM patients, even in the presence of relatively preserved or even preserved LV systolic function. 13, 26 Indeed, almost one quarter of our HF population (n=16 or 23%) was comprised patients with EF≥50%, ie, never fulfilling the classic definition proposed for end-stage disease. Because HCM is a hyperdynamic disease, the bar used to define LV dysfunction should be set higher than in other cardiovascular conditions, so that LVEF values approaching 55% should already be regarded with a measure of clinical suspicion. 3, 23 Indeed, disease severity may be underestimated if a 50% LVEF cutoff is used, and the window of opportunity for decisive therapeutic options such as HT may be missed. 8, 13 It is worth noting that the rapid progression of symptomatic HF is often preceded by an extended period-9 years from diagnosis in the present cohort and 5 in the article by Harris et al 4 -during which warning signs may be present, often insidious and subclinical, allowing early identification of patients at risk. Features such as dilated left atrium, onset of AF, 3, 11 severe microvascular dysfunction, 9, 27 increasing extension of LV fibrosis, 23 elevated plasma levels of natriuretic peptides, 28, 29 and declining oxygen consumption rates, 30, 31 all represent potentially useful red flags, particularly when assessed serially over time. A comprehensive knowledge of the HF spectrum, combined with surveillance strategies based on imaging, cardiopulmonary testing and biomarkers, may significantly anticipate the identification of patients who might benefit from advanced treatment options and reduce the rate of exclusion from-or failure of-HT. 32 In these patients, an early switch from standard HCM therapy to HF β-blockers, angiotensin-converting enzyme-inhibitors/ angiotensin receptor blockers and antialdosterone agents may contrast disease progression, whereas the search for more disease-specific treatment options is ongoing. 33 
Time Frame of HF-Related Outcome: Implications for HT
During an average follow-up of 6.1 years after the onset of NYHA class III to IV symptoms, one half of the 71 study patients died, largely because of HF-related complications including cardioembolic stroke. The 5-year prevalence for the combined end point including all-cause mortality, HT, or appropriate ICD shocks was as high as 62%. Notably, the rate of these events was not uniform over time; rather, it seemed to be skewed toward the first 3 years after HF onset, during which the end point was frequent (17% per year). This is consistent with the report by Harris et al, 4 in which the average interval between onset of end-stage HCM (defined by an LVEF<50%) and death or HT was 2.7 years. In contrast, during subsequent follow-up, only 3% of our patients with HF annually reached the combined end point-an ≈6-fold decrease in risk, suggesting the emergence of milder forms with more gradual clinical decline. 3, 26 Our findings have important implications for management, suggesting that the window of opportunity for HT after onset of HF symptoms may be short in HCM. [13] [14] [15] [16] When implemented in a timely fashion, HT represented an excellent option in our cohort, with results in agreement with previous reports. [14] [15] [16] Of note, Maron et al 16 reported a 75% 5-year survival post HT, supporting the view that HT is the only option to restore longevity among patients with HCM with advanced HF. 11
ICD, Cardiac Resynchronization Therapy, and Pharmacological Therapy of HF
Overall, 11 patients (of 34 implanted) experienced appropriate ICD interventions because of fast VT or VF; of these, 5 subsequently died and 1 underwent HT. Therefore, our data support the view that advanced HF in patients with HCM should prompt consideration for an ICD, irrespective of LVEF, in all nonobstructive patients with advanced HF symptoms, whether intended as a bridge to HT or as a long-term prophylaxis. 1, 2, 4 The possibility of adding cardiac resynchronization therapy (instituted in 13 of our patients) seems reasonable in patients with EF<50% and QRS duration >120 ms. However, criteria identifying potential responders in HCM are unresolved and presumably different from those of classic systolic HF, deserving further investigation. 2
Conclusions
In HCM, advanced HF symptoms not associated with outflow tract obstruction portends severely unfavorable prognosis, particularly in the first 3 years after onset of such symptoms, despite frequently preserved systolic function in about one quarter of the patients. Outcome of HT is favorable but requires early consideration because the window of opportunity may be short. 
